Who Paid My Doc
Barry Uretsky
Cardiovascular Disease Little Rock, AR Medical Doctor
NPI 1316009731 CMS profile 58857
4301 Marham Avenue, S-304 Shorey Building, Little Rock, AR 72205
General payments
$36,031
Research payments
$10,593
Ownership & investment interest
$0
Research they led as principal investigator
$572,504
Through program year 2025, Barry Uretsky of Little Rock, AR is reported in the CMS Open Payments database as having received $36,031 across 87 general payments and $10,593 in research payments paid to them. Separately, studies naming them as principal investigator received $572,504 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 93rd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,060 | 12 | |
| 2024 | General | $741 | 8 | |
| 2023 | General | $674 | 8 | |
| 2022 | General | $1,598 | 21 | |
| 2022 | Research | $10,593 | 2 | |
| 2021 | General | $287 | 3 | |
| 2020 | General | $1,643 | 5 | |
| 2019 | General | $30,027 | 30 |
Beside peers
- Barry Uretsky
- Cardiovascular Disease median
- Middle half of Cardiovascular Disease
- National median
In program year 2025, general payments to Barry Uretsky were reported at $1,060. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.
Show as a table
| Year | Barry Uretsky | Cardiovascular Disease median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $30,027 | $450 | $127–$1,392 | $163 |
| 2020 | $1,643 | $242 | $77–$751 | $114 |
| 2021 | $287 | $335 | $101–$1,037 | $132 |
| 2022 | $1,598 | $395 | $121–$1,211 | $149 |
| 2023 | $674 | $443 | $136–$1,283 | $160 |
| 2024 | $741 | $450 | $136–$1,323 | $164 |
| 2025 | $1,060 | $432 | $132–$1,252 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
89 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Cardiovascular Disease in Arkansas
Ian Cawich
Cardiovascular Disease · Little Rock, AR
Barry Tedder
Cardiovascular Disease · Jonesboro, AR
Harvinder Dod
Cardiovascular Disease · El Dorado, AR
William Rollefson
Cardiovascular Disease · Little Rock, AR
Andre Paixao
Cardiovascular Disease · Little Rock, AR
Julio Schwarz
Cardiovascular Disease · Fort Smith, AR
Related records
Cardiovascular Disease in Arkansas
Practitioners in the same specialty and state, ranked by reported value.
All Cardiovascular Disease
Everyone recorded under this specialty, nationwide.
Doctors in Arkansas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.